Stock & Company Details
Viatris Inc $VTRS
Price:
N/A
N/A
1.1B
$20B
52 Week High:
N/A
10 Day Average Volume:
N/A
-48.84
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
VTRS technical indicators
Latest Viatris Inc (VTRS) indicator readings as of 2026-10-09.
VTRS's 14-day RSI is 57.5, in neutral territory. At $17.64 it is trading 14.1% above its 200-day moving average of $15.46, and above its 50-day average of $16.93. Price sits in the middle of its Bollinger Bands ($16.56 to $18.23). ADX reads 23.6, sitting between trending and range-bound.
VTRS backtested strategy results
How 4 rule-based strategies performed on Viatris Inc (VTRS) over recent history, last backtested 2026-09-09. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +82.8% | 57% | 14 | -19.0% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | +26.6% | 43% | 21 | -45.6% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | +61.9% | 42% | 26 | -17.5% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | -15.2% | 58% | 26 | -31.3% |
Overview
Viatris Inc. is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. It provides access to medicines, advance sustainable operations, develop innovative solutions and leverage its collective expertise to connect more people to more products and services through its one-of-a-kind Global Healthcare GatewayTM. Formed in November 2020through the combination of Mylan and Pfizer's Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghaiand Hyderabad, India.
Finance Bot
Ask your questions
Start by typing a question below.
